iBio, Inc. IBIO

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

iBio, Inc. (also referred to as "we", "us", "our", "iBio", or the "Company") is a clinical-stage biotechnology company leveraging the power of Artificial Intelligence ("AI") for the development of hard-to-drug precision antibodies for obesity, cardiometabolic and cardiopulmonary diseases. Our core mission is to harness the potential of AI and machine learning ("ML") to unveil novel biologics which other scientists have been unable to develop. Through our innovative AI Drug Discovery Platform, we have been able to identify differentiated molecules aimed at addressing unmet needs by current approved therapies.

We believe the future treatment for obesity lies not just in overall weight loss, but in the quality, durability, and tolerability of weight loss. Current interventional therapies, such as glucagon-like peptide-1 ("GLP-1") receptor agonists have ushered in a breakthrough era, yet challenges remain: muscle loss, fat regain after treatment cessation, and long-term tolerability. We are developing next-generation therapies designed with the goal of meeting these unmet needs, by leveraging AI-guided antibody design, advanced screening technologies and deep expertise in biologics development.

Last close 0.71 2026-10-26
Market cap $45.5M 2026-06-30 share count
52-week range 0.69 - 3.82

Valuation FY2026 figures against the last close

P/S454.7x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.32

Annual financial statements

Income statement

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $100.0K$400.0K$225.0K$0$1.9M$2.4M$1.6M$37.0K$44.0K$394.0K
Cost of revenue ————$216.0K$1.5M$703.0K———
Gross profit ————$2.2M$909.0K$935.0K———
R&D $19.6M$8.3M$5.2M$10.3M$9.8M$10.0M$3.6M$5.5M$4.0M$4.1M
SG&A $10.6M$10.7M$11.7M$19.0M$21.8M$22.0M$11.4M$12.3M$10.7M$10.6M
Total operating expenses $35.2M$19.0M$16.9M$29.3M$31.6M$32.0M$14.9M$17.8M$14.7M$14.7M
Operating income -$35.1M-$18.6M-$16.6M-$29.3M-$29.7M-$31.1M-$14.0M-$15.8M-$14.2M-$14.3M
Interest expense $53.0K$212.0K$172.0K$83.0K$1.4M$2.5M$2.5M$1.9M$1.9M$1.9M
Pre-tax income -$33.0M-$18.4M-$24.9M-$65.0M-$50.3M-$23.2M-$16.4M-$17.6M-$16.1M-$14.5M
Income tax $0$0$0$0$0$0$0$0$0$0
Net income -$32.8M-$18.4M-$24.9M-$65.0M-$50.3M-$23.2M-$16.4M-$17.6M-$16.1M-$14.5M
EPS, basic -0.32-1.75-6.50-106.19-5.78-3.00————
EPS, diluted -0.32-1.75-6.50-106.19-5.78-3.00-0.61-0.94-1.54-1.64
Shares, diluted (wtd. avg.) 104.1M10.5M3.8M612,0008.7M7.8M————

Balance sheet

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $56.4M$8.6M$14.4M$7.6M$28.7M$77.4M$55.1M$4.4M$4.4M$15.9M
Short-term investments $31.6M—————————
Receivables ——$0$0$1.0M$426.0K$75.0K$97.0K$75.0K$175.0K
Inventory ——$0$0$3.9M$27.0K————
Total current assets $92.2M$9.7M$15.7M$26.3M$45.1M$104.6M$61.7M$4.8M$16.3M$8.6M
Property, plant and equipment $3.1M$3.2M$3.6M$4.2M$1.4M$8.6M$3.7M$24.4M$25.2M$25.6M
Other intangibles $1.8M$6.8M$5.4M$5.4M$4.9M$952.0K$1.1M$1.4M$1.6M$1.8M
Total assets $99.1M$23.2M$28.7M$41.2M$99.4M$147.0M$94.2M$30.6M$43.1M$36.0M
Accounts payable $4.4M$2.2M$358.0K$1.8M$4.3M$2.3M$1.8M$1.0M$790.0K$749.0K
Total current liabilities $11.7M$6.1M$3.8M$22.1M$30.4M$6.6M$5.2M$3.5M$2.0M$2.0M
Total liabilities $13.4M$8.3M$7.4M$25.8M$35.9M$38.4M$37.6M$28.1M$26.9M$27.1M
Retained earnings -$365.3M-$332.2M-$313.8M-$288.9M-$223.9M-$173.6M-$150.4M-$105.8M-$88.2M-$72.1M
Total equity $85.7M$14.9M$21.3M$15.4M$63.5M$108.6M$56.6M$2.5M$16.2M$8.9M

Cash flow

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow -$23.2M-$15.3M-$18.6M-$30.4M-$37.5M-$30.1M-$13.3M-$14.0M-$13.5M-$13.2M
Depreciation and amortisation $558.0K$484.0K$638.0K$674.0K$2.3M$472.0K$282.0K$1.4M$1.4M$1.3M
Stock-based compensation $1.4M$1.5M$2.0M$4.4M$4.4M$1.6M$388.0K$241.0K$770.0K$1.0M
Capital expenditure $578.0K$16.0K$210.0K$5.7M$7.3M$4.9M$1.1M$920.0K$934.0K$1.3M
Investing cash flow -$32.0M$742.0K$906.0K$7.0M-$5.1M-$26.5M-$1.2M-$990.0K-$1.1M-$1.6M
Financing cash flow $103.0M$8.9M$24.5M$2.3M-$6.1M$78.8M$65.2M$3.5M$22.4M-$170.0K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001420720-26-000022.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -80M -60M -40M -20M 0 20M Revenue, FY2017: 394K Net income, FY2017: -14.5M Revenue, FY2018: 44K Net income, FY2018: -16.1M Revenue, FY2019: 37K Net income, FY2019: -17.6M Revenue, FY2020: 1.6M Gross profit, FY2020: 935K Net income, FY2020: -16.4M Revenue, FY2021: 2.4M Gross profit, FY2021: 909K Net income, FY2021: -23.2M Revenue, FY2022: 1.9M Gross profit, FY2022: 2.2M Net income, FY2022: -50.3M Revenue, FY2023: 0 Net income, FY2023: -65M Revenue, FY2024: 225K Net income, FY2024: -24.9M Revenue, FY2025: 400K Net income, FY2025: -18.4M Revenue, FY2026: 100K Net income, FY2026: -32.8M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue $394.0K $44.0K $37.0K $1.6M $2.4M $1.9M $0 $225.0K $400.0K $100.0K
Gross profit — — — $935.0K $909.0K $2.2M — — — —
Net income -$14.5M -$16.1M -$17.6M -$16.4M -$23.2M -$50.3M -$65.0M -$24.9M -$18.4M -$32.8M

Recent filings and events

  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Director nominations Dates and mechanics for shareholders proposing directors. Item 5.08
  • Other event Item 8.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event Item 8.01
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.7x 44.7%
JNJ JOHNSON & JOHNSON $641.76B 24.1x 6.0%
ABBV AbbVie Inc. $506.70B 121.5x 8.6%
MRK Merck & Co., Inc. $346.91B 19.3x 1.3%
ABT ABBOTT LABORATORIES $182.68B 28.2x 5.7%
PFE PFIZER INC $169.79B 21.9x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $131.16B 33.8x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.85B 17.8x -0.2%